Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations

doi:10.5306/wjco.v8.i3.230

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10904)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

1007

WORD

378

HTML

5131

Figures (1-3)

186

Sum=6702

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

595

Download

831

Sum=1426

Publishing Process of This Article

Item

Count

Browse

1311

Download

1465

Sum=2776

Jun 10, 2017 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (45)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Jun 10, 2017; 8(3): 230-240
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.230

Full Size Figure Download Figure

Figure 3 Searching for the optimal combination to maximize the potential of immune checkpoint blockade for the treatment of pancreatic cancer. CTLA-4: Cytotoxic T lymphocyte antigen-4; PD-1: Programmed cell death protein-1; PD-L1: Programmed death ligand-1; CD40: Cluster differentiation 40; CAR T cells: Chimeric antigen receptor T cells; PI3K: Phosphoinositide-3-kinase; BTK: Bruton tyrosine kinase; JAK: Janus kinase; PEGPH20: Pegylated hyaluronidase.

Citation: Guo S, Contratto M, Miller G, Leichman L, Wu J. Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World J Clin Oncol 2017; 8(3): 230-240
URL: https://www.wjgnet.com/2218-4333/full/v8/i3/230.htm
DOI: https://dx.doi.org/10.5306/wjco.v8.i3.230